CD8A and colorectal cancer: The strong potential of these classes of inhibitors was demonstrated in preclinical models of colorectal cancer treated in vivo with nanoparticles loaded with the STAT3 inhibitor BBI608, which resulted in enhanced infiltration of CD4+ and CD8+ TILs at tumor sites and tumor regression (183).